Allgemein Archive - Glycotope

Allgemein

Glycotope to present platform approach for development of anti-GlycoTarget antibodies at 2024 AACR Meeting

8. April 2024 Daniel Gau

Berlin, Germany, 08 April, 2024 – Glycotope GmbH, a biotechnology company utilizing a proprietary platform technology to developing antibodies against proteins carrying tumor-specific carbohydrate structures, today announces that it will present its platform approach and GlycoTarget database in a poster presentation at the 2024 American Association for Cancer Research (AACR) Meeting, being held in San Diego, […]

Allgemein

Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform

11. December 2023 Daniel Gau

Berlin, Germany, 11 December 2023 – Glycotope GmbH (Glycotope) has signed an agreement with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) to combine Glycotope’s antibodies with Evotec’s immune cell engager platform for the development of next generation immune cell engaging bispecifics by Evotec. First generation immune cell engager (ICE) bispecifics have revolutionized […]

Allgemein

Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting

3. November 2023 Daniel Gau

Berlin, Germany, 03 November, 2023 – Glycotope GmbH, a biotechnology company with a proprietary platform technology for developing antibodies against proteins carrying tumor-specific carbohydrate structures, today announces that it will present a poster on antibodies that specifically recognize cancer-associated glycoforms of mucin-like proteins at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting, being held in […]

Allgemein

LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development

16. October 2023 Daniel Gau

LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody for use as Antibody Drug Conjugate Seoul, South Korea, and Berlin, Germany October 16, 2023 – LegoChem Biosciences Inc. (LCB) and Glycotope GmbH (Glycotope) have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate (ADC) by combining LCB’s proprietary ADC technology […]

Allgemein

Glycotope and Max Delbrück Center enter into research collaboration to explore combination of GlycoTargets and CAR technology

25. September 2023 Daniel Gau

Berlin, Germany, 25 September 2023 – Glycotope GmbH (Glycotope) and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (GlycoTargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center. CARs are engineered synthetic receptors that […]

Allgemein

DS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancers

7. September 2023 Philipp Giese

Congratulations to DaiichiSankyo on the commencement of first-in-human trials of DS-3939, which has been developed using a humanized anti-TA-MUC1 antibody with carbohydrate mediated tumor-specificity and high affinity binding, licensed from Glycotope. Press Release: Download here

Allgemein

Glycotope Presents Glyco-Engineered Cell Lines at the 2023 American Association for Cancer Research (AACR) Meeting

17. April 2023 Daniel Gau

Berlin, Germany, 17 April, 2023 – Glycotope GmbH, a biotechnology company utilizing a proprietary platform technology to developing antibodies against proteins carrying tumor-specific carbohydrate structures, today announces that it will present its glyco-engineered cell lines in a poster presentation at the 2023 American Association for Cancer Research (AACR) Meeting, being held in Orlando, Florida, United States, […]

Allgemein

Glycotope Presents Glyco-Engineered Cell Lines at GlycoBioTec 2023 – 3rd International GlycoBioTec Symposium

17. January 2023 Daniel Gau

Berlin, Germany, 17 January, 2023 – Glycotope GmbH, a biotechnology company with a proprietary platform technology for developing antibodies against proteins carrying tumor-specific carbohydrate structures, today announces that it will present its glyco-engineered cell lines at GlycoBioTec 2023 – 3rd International GlycoBioTec Symposium, being held in Berlin, Germany, on 17 and 18 January 2023. Patrik Kehler, […]

Allgemein

Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer

13. December 2022 Daniel Gau

San Diego, U.S.A., Seoul, Korea and Berlin, Germany, 13 December 2022 – Therabest USA. Inc, Therabest Korea (Therabest) and Glycotope GmbH (Glycotope) have signed an agreement to assess the clinical development of Therabest’s EiNKTM (Enhanced iPSC-derived NK) cell therapy, TB-100, in combination with Glycotope’s immuno-cytokine, GT-00AxIL15 in triple-negative breast cancer (TNBC) patients. NK cell therapies from […]

Allgemein

Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting

8. November 2022 Daniel Gau

Berlin, Germany, 08 November, 2022 – Glycotope GmbH, a biotechnology company with a proprietary platform technology for developing antibodies against proteins carrying tumor-specific carbohydrate structures, today announces that it will present new data at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held in Boston, United States, between 8-12 November 2022. Patrik Kehler, […]

Category: Allgemein